Cardiff Oncology (Formerly Trovagene, Inc) is a California based clinical-stage biotechnology company with Onvansertib, indicated for various solid tumors and hematology conditions. Cardiff

Cardiff Oncology, Inc is primarely in the business of biological products (no diagnostic substances). For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Cardiff Oncology, Inc..

Our goal is to overcome resistance, extend duration of response and increase overall survival. We are developing onvansertib, an oral and highly-selective inhibitor of Polo-like Kinase 1 (PLK1), in combination with standard-of-care therapeutics, to overcome resistance to current therapies, improve efficacy and increase overall survival in solid tumor and hematologic cancers. At Cardiff Oncology, our mission is to turn the tide on cancer by developing onvansertib, a first-in-class, third generation Polo-like Kinase 1 (PLK1) inhibitor, to treat cancers with the greatest medical need for new therapeutic options to overcome resistance, improve response and increase overall survival. Cardiff Oncology is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated There is currently only a 4% response rate to second-line standard-of-care (SOC) FOLFIRI/Avastin ® and median progression-free survival (PFS) of 5.5 months..

Cardiff Oncology (formerly Trovagene, Inc.) is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer 5 mar 2021 Indici Cardiff Oncology: profilo societario, assetto del gruppo, attività e posizione competitiva e informazioni sul capitale. Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of The latest Cardiff Oncology Inc USD0.0001 share price. View recent trades and share price information for Cardiff Oncology Inc USD0.0001. 8 Apr 2021 Cardiff Oncology to Host Key Opinion Leader Webinar on Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer - read Cardiff Oncology is a clinical-stage company with the singular mission of developing new oncology therapeutic options for cancer patients. Cardiff Oncology, Inc. Common Stock (CRDF) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Quali strumenti di analisi tecnica possono essere usati per analizzare CARDIFF ONCOLOGY INC? Scopri indicatori, oscillatori, medie mobili e tanti altri 2 days ago Real-time trade and investing ideas on Cardiff Oncology Inc CRDF from the largest community of traders and investors. 6 days ago Cardiff Oncology is a clinical-stage biotechnology company and our mission is to develop new treatment options for cancer patients in How Much Are Cardiff Oncology, Inc. (NASDAQ:CRDF) Insiders Spending On Buying Shares?

Our goal is to overcome resistance, improve response to treatment and increase overall survival.

Cardiff Oncology, San Diego, California. 1,196 likes. We are a clinical stage biotech company developing oncology therapeutics to treat cancer indications with the greatest medical need fo new

2020-09-01 · Cardiff Oncology with onvansertib may pave a new path through some of the most difficult to treat cancers, including those that have been long considered to be untreatable. The only issue may be getting the biotech community on board. Due to the current paradigm of cancer treatment as well as the unconventional mechanism of About Cardiff Oncology, Inc. Cardiff Oncology (formerly Trovagene, Inc.) is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients Cardiff is a small oncology concern based in San Diego. The company has one primary compound 'Onvansertib' in its pipeline which is targeting several different indications in trials.

Cardiff Oncology Inc är en aktie för Cardiff Oncology Inc med ISIN-beteckning US14147L1089.

2021-01-15 · Cardiff Oncology, Inc. NASDAQ: CRDF $9.27 down $0.21 (-2.21%) Related Articles. Why Cardiff Oncology Ran Up 1,350% in 2020; 2 Biotech Stocks That Keep on 2021-04-13 · Cardiff Oncology Inc. Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. Find the latest Cardiff Oncology, Inc. (CRDF) stock quote, history, news and other vital information to help you with your stock trading and investing. Cardiff Oncology Inc är en aktie noterad som CRDF, som inte betalar utdelning.

Get the latest Cardiff Oncology, Inc. CRDF detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Cardiff Oncology is a clinical-stage oncology therapeutics company developing drugs that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers. It has a broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Corporate Governance. Cardiff Oncology, Inc.’s ISS Governance QualityScore as of N/A is N/A. Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. Its lead drug candidate is onvansertib, a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor that is in Phase Ib/II clinical trial in acute myeloid leukemia (AML); has completed a Phase I clinical trial in advanced solid tumors; and Phase Ib/II clinical trial for Cardiff Oncology is a biotech that should be on your radar.That's because it just recently reported positive results using its drug onvansertib to treat patients with KRAS mutated metastatic Cardiff Oncology, San Diego, California.
Släp 750kg

Klicka här för att följa aktiekursen i realtid. Få omedelbar tillgång till detaljerad information om tekniska analyser och handelssignaler för Cardiff Oncology Inc aktien. Den här sidan ger en fördjupad profil av Cardiff Oncology Inc, inklusive en allmän översikt av företagets affärsverksamhet och ansvarig ledning.

2. 2021-4-8 Cardiff Oncology is a biotech company. The company develops therapies and treatments for solid tumor and hematologic cancers. It provides onvansertib, a Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.
Fredrik nordling

2021-4-13 · Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of …

Cardiff Cardiff oncology has trials of onvansertib ongoing in several indications, including AML, castrate resistant prostate cancer, and metastatic colorectal cancer. My investment thesis in Cardiff Cardiff is a small oncology concern based in San Diego. The company has one primary compound 'Onvansertib' in its pipeline which is targeting several different indications in trials.

Cardiff Oncology Inc. published this content on 05 October 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 October 2020 20:19:01 UTC

Academic modules will include the anatomy, physiology, oncology and radiotherapy management of cancer within the abdomen, pelvis, head and neck and central nervous system (CNS), as well as radiotherapy treatment planning. Cardiff Oncology (Formerly Trovagene, Inc) is a California based clinical-stage biotechnology company with Onvansertib, indicated for various solid tumors and hematology conditions. Cardiff Cardiff Oncology (NASDAQ:CRDF) last announced its quarterly earnings data on Thursday, February 25th. The company reported ($0.19) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.05). Cardiff Oncology had a negative net margin of 4,990.52% and a negative return on equity of 95.03%. 2021-4-12 · Cardiff Oncology to Host Key Opinion Leader Webinar on Onvansertib for the Treatment of KRAS-Mutated Metastatic Colorectal Cancer -- Virtual event will take place on Monday, April 12, 2021 at 11 a.m. ET and will include a Q&A session Mar 11, 2021 Cardiff Oncology to Present at the Oppenheimer 31st Annual Healthcare Conference Historical daily share price chart and data for Cardiff Oncology since 2021 adjusted for splits.

As of March 31st, there was short interest totalling 2,650,000 shares, a decrease of 51.0% from the March 15th total of 5,410,000 shares.